Castle Biosciences (CSTL) Non-Current Debt (2018 - 2026)

Castle Biosciences has disclosed Non-Current Debt across 6 years of filings, most recently posting $8.4 million for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $8.4 million, down 5.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.4 million (down 5.85% YoY), and the FY2025 annual result was $9.6 million, down 1.08% from the prior year.
• Non-Current Debt came in at $8.4 million for Q1 2026 at Castle Biosciences, down from $9.6 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $10.0 million in Q3 2025 to a low of $8.1 million in Q2 2025.
• The 3-year median for Non-Current Debt is $9.7 million (2024), against an average of $9.4 million.
• Peak annual rise in Non-Current Debt reached 0.34% in 2025, while the deepest fall reached 19.1% in 2025.
• Castle Biosciences' Non-Current Debt stood at $9.7 million in 2024, then retreated by 1.08% to $9.6 million in 2025, then decreased by 12.87% to $8.4 million in 2026.
• The last three Non-Current Debt figures came in at $8.4 million (Q1 2026), $9.6 million (Q4 2025), and $10.0 million (Q3 2025), per Business Quant data.